PD-L1 and c-MET expression and survival in patients with small cell lung cancer
Authors:
Open Access
- 1 June 2017
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (33) , 53978-53988
Abstract
PD-L1 and c-MET expression and survival in patients with small cell lung cancer PD-L1 and c-MET expression and survival in patients with small cell lung cancerKeywords
This publication has 45 references indexed in Scilit:
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune EscapeScience Translational Medicine, 2012
- Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomasLaboratory Investigation, 2012
- MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell linesBritish Journal of Cancer, 2011
- Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanomaCancer, 2010
- PD‐1 signaling in primary T cellsImmunological Reviews, 2009
- Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular CarcinomaClinical Cancer Research, 2009
- Small Cell Lung Cancer: Have We Made Any Progress Over the Last 25 Years?The Oncologist, 2007
- Expression of c‐met/HGF Receptor in Human Non‐small Cell Lung Carcinomas in vitro and in vivo and Its Prognostic SignificanceJapanese Journal of Cancer Research, 1996